Among the emerging therapeutic targets, IL-23 has gained considerable attention, due to its critical pathogenetic role, mainly promoting expansion and survival of T helper (Th)-17 lymphocytes–a role also undertaken in other IMID, such as psoriasis and psoriatic arthritis, for which IL-23 inhibitors offer an effective and safe therapeutic option [5]. Here, IL37 is linked to psoriasis.